Astrana Health Reports Earnings Thursday After Last Quarter's Guidance Went Unmentioned

Astrana Health (ASTH) reports first-quarter 2026 earnings after the close on May 7, 2026, with the stock trading at $35.25 heading into the release. The healthcare services company faces a critical test: can it deliver on aggressive growth expectations after a volatile year of earnings surprises, or will execution challenges continue to weigh on results? With analysts projecting a dramatic turnaround and the stock up sharply in recent weeks, tomorrow's report will determine whether the recent rally has legs.

Part 1: Earnings Preview

Astrana Health operates as a physician-centric, technology-powered healthcare services company, managing care for over 1 million patients through its network of affiliated physician groups across multiple states. The company focuses on value-based care arrangements, capitated risk contracts, and population health management—a model that has driven rapid revenue growth but created earnings volatility as the business scales.

For Q1 2026 ending March 31, analysts expect earnings of $0.29 per share on revenue of approximately $949 million, representing +107.14% year-over-year EPS growth compared to $0.14 reported in Q1 2025. The most recent quarter (Q4 2025) delivered $0.54 per share, crushing estimates of $0.15 by 260% and providing a strong setup heading into this release. The dramatic year-over-year comparison reflects both the prior year's weakness and expectations for improved operational execution as the company integrates recent acquisitions and matures its risk-bearing contracts.

Three key themes define this earnings story:

Revenue Growth and Contract Performance: With revenue expected to surge 53% year-over-year to nearly $950 million, investors will scrutinize whether Astrana can maintain its aggressive growth trajectory while improving profitability. The company's value-based care model depends on accurately pricing risk and managing medical costs—any deterioration in medical loss ratios or contract performance could derail the growth narrative.

Earnings Quality and Consistency: After three consecutive quarters of significant misses (Q1-Q3 2025) followed by a massive Q4 beat, the market is demanding proof that earnings can stabilize. The wild swings—from a 97.87% miss in Q3 to a 260% beat in Q4—have created skepticism about forecasting accuracy and operational predictability. This quarter needs to demonstrate that Q4 wasn't an anomaly.

Integration Execution and Margin Expansion: As Astrana digests its physician network acquisitions and scales its technology platform, analysts are watching for evidence that the company can convert revenue growth into sustainable margin improvement. The sharp downward revision in full-year 2026 EPS estimates (from $2.20 to $1.44) suggests analysts remain cautious about near-term profitability despite strong revenue momentum.

Analyst commentary ahead of the release reflects cautious optimism tempered by execution concerns. With 8 Strong Buy ratings and an average price target of $36.89 (4.7% above current levels), the Street sees value but wants confirmation that the business model can deliver consistent results at scale.

Part 2: Historical Earnings Performance

Astrana Health's recent earnings history reveals extreme volatility that has tested investor confidence. Over the past four quarters, the company posted three significant misses followed by one dramatic beat—a pattern that raises questions about forecasting accuracy and operational predictability.

The deterioration began in Q1 2025, when ASTH reported $0.14 versus estimates of $0.23 (a 39.13% miss), followed by an even wider miss in Q2 ($0.19 vs. $0.36, down 47.22%). The situation reached a nadir in Q3 2025 with a near-total earnings collapse: just $0.01 per share against expectations of $0.47, representing a staggering 97.87% shortfall. This three-quarter stretch of deteriorating results hammered the stock and forced analysts to dramatically lower their estimates.

The Q4 2025 reversal was equally dramatic: ASTH delivered $0.54 per share against estimates of just $0.15, a 260% beat that represented the company's strongest quarterly performance in recent memory. This massive surprise suggests either a significant one-time benefit, a sharp operational turnaround, or—most concerning for forecasting—continued difficulty in modeling the business. The question heading into Q1 2026 is whether Q4 marked an inflection point or simply another data point in an unpredictable earnings stream. Investors need to see consistency, not just occasional outperformance, to rebuild confidence in the company's ability to execute its growth strategy.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Astrana Health typically reports earnings after market close, meaning Day 0 captures anticipatory trading before results are released, while Day +1 reflects the market's first full session to digest the actual numbers.

Historical price behavior around earnings shows significant volatility, with an average absolute Day 0 move of 5.12% and Day +1 move of 15.14%—well above typical market reactions. The most dramatic recent example came with the March 2026 report (Q4 2025 results), when the stock surged 29.46% on Day 0 in anticipation, then pulled back 6.88% the following session as traders took profits despite the strong beat.

The pattern reveals that ASTH tends to see its largest moves on Day +1 rather than Day 0, with an average Day +1 range of 16.12% compared to 5.34% on Day 0. This makes sense given the after-hours reporting schedule—the real price discovery happens the next trading day. Notable volatility spikes include the November 2025 report (23.46% Day +1 decline despite a modest Day 0 move) and the August 2025 report (30.85% Day +1 surge following a modest Day 0 decline). The wide ranges and large directional moves reflect the market's struggle to price a business model with unpredictable quarterly results. Investors should expect substantial two-way risk around this release, with historical data suggesting moves of 10-20% are well within normal bounds.

Part 2.2: Options Market Expected Move

The options market is pricing a 6.32% expected move through the May 15 expiration (9 days out), implying a range of $33.02 to $37.48. This is notably more conservative than the stock's historical average absolute Day +1 move of 15.14%, suggesting options traders may be underpricing post-earnings volatility risk. Given ASTH's track record of double-digit swings following results, the current options pricing may present opportunity for volatility buyers or risk for those selling premium into the event.

Part 3: What Analysts Are Saying

Analyst sentiment on Astrana Health remains strongly bullish despite the stock's recent volatility, with the consensus reflecting confidence in the long-term value-based care thesis even as near-term execution questions persist. The current average recommendation of 4.42 out of 5.0 places ASTH firmly in buy territory, supported by 8 Strong Buy ratings, 1 Moderate Buy, and 3 Hold ratings—with zero sell recommendations across the 12 analysts covering the stock.

The average price target of $36.89 implies modest 4.7% upside from the current $35.25 price, though the range of estimates reveals divergent views on valuation. The high target of $50.00 suggests some analysts see 42% upside potential if the company can execute on its growth strategy and stabilize margins, while the low target of $26.00 implies 26% downside risk if operational challenges resurface. This wide 24-point spread reflects genuine uncertainty about the company's ability to convert revenue growth into consistent profitability.

Critically, analyst sentiment has remained unchanged over the past month according to the sentiment trend indicator, suggesting the Street is taking a wait-and-see approach heading into earnings rather than adjusting views preemptively. The stability in ratings despite recent stock strength indicates analysts want confirmation that Q4's blowout results weren't an anomaly before becoming more aggressive with targets. The concentration of Strong Buy ratings (8 of 12 analysts) demonstrates conviction in the business model, but the lack of recent upgrades suggests the bar is high for this earnings report to drive further multiple expansion.

Part 4: Technical Picture

Astrana Health enters earnings with strong technical momentum and a supportive setup across multiple timeframes. The Barchart Technical Opinion currently stands at 88% Buy, up sharply from 72% Buy one week ago and 24% Buy one month ago—a dramatic strengthening that reflects the stock's recent breakout above key resistance levels.

Timeframe Analysis:

• Short-term (100% Buy): Maximum bullish signal indicates powerful near-term momentum as the stock extends its rally into earnings
• Medium-term (100% Buy): Equally strong reading confirms the uptrend is well-established beyond just short-term trading, suggesting institutional accumulation
• Long-term (50% Buy): Moderate positive signal shows improving longer-term trend structure, though not yet at the strength of shorter timeframes

Trend Characteristics: The Strong and Strengthening trend environment heading into earnings provides a supportive backdrop, with momentum clearly in bulls' favor and technical deterioration minimal even as the stock approaches potential resistance.

The stock is trading above all major moving averages, a bullish alignment that confirms the uptrend: $35.25 versus the 5-day MA at $34.89, 20-day at $32.39, 50-day at $27.56, and 200-day at $26.56. The widening gap above the 50-day and 200-day averages (28% and 33% respectively) shows accelerating momentum but also raises the stakes for earnings—any disappointment could trigger profit-taking back toward the rising 20-day average near $32. The technical setup is clearly supportive heading into the release, but the extended nature of the rally means the stock has less cushion to absorb a negative surprise. A beat-and-raise scenario could propel ASTH toward the $37-38 zone (approaching analyst high targets), while a miss would likely find initial support at the 20-day MA with stronger support at the 50-day near $27.50.